ServiceUpdated on 23 June 2026
Colorectal cancer diagnostic testing
Clinical Director at CanSense Ltd
About
The CanSense IVD system measures spectral signatures from patient samples which provides a cancer risk-score as compared to a trained machine learning algorithm.
The test can be used as a research use only indication to support clinical trials in the colorectal cancer space and as a surrogate endpoint marker in novel drug trials.
Type
- Research & Development
- Testing & Analysis
Organisation
Similar opportunities
Project cooperation
Clinical trial sites for clinical performance Study in colorectal cancer
- Technical
- Capital contribution
- Strategic Partnership
- Completing the consortia
- Consortium seeks Partners
- Technological contribution
- Design - setting the project scope
Dean Harris
Clinical Director at CanSense Ltd
Investment
- Series A | Scale business
Dean Harris
Clinical Director at CanSense Ltd
Project cooperation
Seeking Pharma Co-Development Partner | World's First RAGE-Targeted ADC | Solid Tumour Oncology
- Technical
- Capital contribution
- Strategic Partnership
- Technological contribution
Gareth Morgan
CEO at Viamab Therapeutics L